Fundies.
English

OHR PHARMACEUTICAL INC

EDGAR
NBSE Quarterly report (10-Q) · filed 2023-11-09

109 filing records in this dataset, filed from 2003-08-08 to 2023-11-09. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments
Watchlist
Cash and cash equivalents
12.6 million Unit_Standard_USD_FLJB_hVYx0urFVmD1VbDVA Source
Exact value

12570359 Unit_Standard_USD_FLJB_hVYx0urFVmD1VbDVA

Long-term debt including current maturities
Not available
Shares outstanding
3.73 million Unit_Standard_shares_d_psVXvKIE6KSbVUnjWMzw Source
Exact value

3729206 Unit_Standard_shares_d_psVXvKIE6KSbVUnjWMzw

Company performance

Up to ten complete financial years · consolidated figures

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-11-09.

Financial data available through: 2022-09-30.

Coverage by financial measure
  • revenue: No compatible figures in this window
  • Operating income: 2 of 11 periods available· newest 2022-09-30
  • Net income: 2 of 11 periods available· newest 2022-09-30
  • Operating cash flow: 2 of 11 periods available· newest 2022-09-30
  • Capital expenditure: 2 of 11 periods available· newest 2022-09-30
  • Total assets: Multiple units; comparison withheld· newest 2022-09-30
  • Total liabilities: Multiple units; comparison withheld· newest 2022-09-30
  • Current assets: Multiple units; comparison withheld· newest 2022-09-30
  • Current liabilities: Multiple units; comparison withheld· newest 2022-09-30
  • Cash and cash equivalents: Multiple units; comparison withheld· newest 2022-09-30
  • long term debt: No compatible figures in this window
  • Shares outstanding: Multiple units; comparison withheld· newest 2022-09-30

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

  • Net income

    −Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw 8.37 million

    Prior period

    −Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw 25.41 million

    –

    Current period

    −Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw 33.78 million

    –

    Exact inputs and evidence

    -33776450 − -25409301 = -8367149 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw

    -25409301 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw · 2020-10-01 – 2021-09-30

    Inspect prior input Prior source

    -33776450 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw · 2021-10-01 – 2022-09-30

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Operating cash flow

    −Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw 10.14 million

    Prior period

    −Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw 18.87 million

    –

    Current period

    −Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw 29.01 million

    –

    Exact inputs and evidence

    -29011966 − -18873684 = -10138282 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw

    -18873684 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw · 2020-10-01 – 2021-09-30

    Inspect prior input Prior source

    -29011966 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw · 2021-10-01 – 2022-09-30

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Capital expenditure

    -67.2%

    Prior period

    Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw 1.44 million

    –

    Current period

    Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw 471,711

    –

    Exact inputs and evidence

    471711 − 1438415 = -966704 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw

    1438415 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw · 2020-10-01 – 2021-09-30

    Inspect prior input Prior source

    471711 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw · 2021-10-01 – 2022-09-30

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.
Values and sources
Revenue values and source evidence
PeriodSeriesValueSource evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.
Values and sources
Revenue growth values and source evidence
PeriodSeriesValueSource evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.
  • Operating margin
  • Net margin
  • Free cash flow margin
Values and sources
Profit margins values and source evidence
PeriodSeriesValueSource evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.
Values and sources
Operating cash flow values and source evidence
PeriodSeriesValueSource evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.
Values and sources
Free cash flow values and source evidence
PeriodSeriesValue(Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw)Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.
Values and sources
Liabilities to assets values and source evidence
PeriodSeriesValueSource evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.
Values and sources
Current assets to current liabilities values and source evidence
PeriodSeriesValueSource evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
PeriodNet incomeOperating cash flowCapital expenditureFree cash flow
2021 2020-10-01 – 2021-09-30
−Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw 25.41 million
Exact value

Exact value: -25409301 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw

2020-10-01 – 2021-09-30: -25409301 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw 18.87 million
Exact value

Exact value: -18873684 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw

2020-10-01 – 2021-09-30: -18873684 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw 1.44 million
Exact value

Exact value: 1438415 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw

2020-10-01 – 2021-09-30: 1438415 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw 20.31 million
Calculation and evidence

-18873684 − 1438415 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw

Exact free cash flow: -20312099 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw

Share or cite

The citation records this snapshot. The page link may show a newer release later.

2022 2021-10-01 – 2022-09-30
−Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw 33.78 million
Exact value

Exact value: -33776450 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw

2021-10-01 – 2022-09-30: -33776450 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw 29.01 million
Exact value

Exact value: -29011966 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw

2021-10-01 – 2022-09-30: -29011966 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw 471,711
Exact value

Exact value: 471711 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw

2021-10-01 – 2022-09-30: 471711 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw 29.48 million
Calculation and evidence

-29011966 − 471711 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw

Exact free cash flow: -29483677 Unit_Standard_USD_Cnf9JGFhfEqXJcI8i8kdbw

Share or cite

The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

109 filings · 3,335 latest values · 3,335 originally reported values

Dataset published . Source filing dates and reporting periods are shown separately.

Identifiers: 0001173281, 1173281, NBSE, OHRP, edgar:1173281

Also known as BBM HOLDINGS, INC., NEUBASE THERAPEUTICS, INC., NEUBASE THERAPEUTICS, INC., NeuBase Therapeutics, Inc., OHR PHARMACEUTICAL INC, Ohr Pharmaceutical Inc, PRIME RESOURCE INC